Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys

Kenya Medical Research Institute (KEMRI)

Status

Completed

Conditions

HIV-1-infection

HPV Infection

HPV Vaccine

Treatments

Drug: Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT04711265

KENYAMRI

Details and patient eligibility

About

Longitudinal observational cohort study and extension of the MISP ID: 38406 'immunogenicity and safety of quadrivalent human papillomavirus vaccine in HIV-infected pre-adolescent girls and boys in Kenya'.

Full description

We evaluated for persistence of HPV antibody by measuring titers to specific HPV types 6, 11, 16 and 18 at re-enrollment month 24 , 36 and 48 months in addition to month 7 and 12, after initial vaccination. This provided data for immunogenicity among HIV-infected children for approximately 48 months after initial vaccination. We assessed decline over study intervals in HPV type-specific antibodies.

Enrollment

176 patients

Sex

All

Ages

9 to 14 years old

Volunteers

No Healthy Volunteers

Inclusion criteria